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OBJECTIVES: to evaluate “real life” incidence and independent predictors of major bleeding defined in ACS patients treated with PCI and current standard antithrombotic therapy with prasugrel or ticagrelor.
METHODS AND RESULTS: The RENAMI project is a multicentre retrospective observational registry enrolling 4424 patients with ACS treated with PCI and prasugrel or ticagrelor plus aspirin. Primary endpoint was MACE (major adverse cardiovascular events). Secondary endpoints included each component of MACE, cardiovascular death (CV death), recurrence of ACS (reACS) and stroke. Eighty three (1.8%) patients developed out of hospital major bleedings after 14.1 ± 6.2 months. These patients had higher rates of MACE (14.5% vs 4.4%; p=0.001) and of all-cause death (11% vs 2.1%; p<0.001). Independent predictors of major bleeding were age > 75 years (OR 2.00; 95% CI 1.18-3.41; p=0.010) and female sex (OR 1.66; 95% CI 1.02-2.70; p=0.041). BARC 3-5 bleeding was independently associated with all-cause mortality (OR 3.46; 95% CI 1.64-7.31; p 0.001).







Worldwide, acute coronary syndrome (ACS) is the single most frequent cause of death. In 2015 an estimated 7.4 million people died from ACS, accounting for 13.1% of all deaths (1). While the incidence of STEMI has decreased appreciably over the last decade, the rate of NSTEMI has slightly increased (2). 
Percutaneous coronary intervention (PCI) has represented a turning point for ACS treatment offering satisfactory results even in high risk patients or procedures (3-5). Dual-antiplatelet therapy with an oral P2Y12 receptor inhibitor is a cornerstone of treatment in patients with ACS undergoing PCI (6-8). Prasugrel and ticagrelor as compared with clopidogrel have been associated with a significantly reduction in cardiovascular death, myocardial infarction and stroke, although a significant increase in the risk of major bleeding, including fatal one, for prasugrel and in the rate of non CABG-related bleedings for ticagrelor, has been reported (9,10). 
In general, haemorrhagic complications occur with a frequency of 1% to 10% during treatment for ACS (11-13), and major bleeding is currently one of the most common non-cardiac complications in these patients (13,14). However, only few data have been provided about real world incidence in patients treated with an oral P2Y12 receptor inhibitor (15). 







Patients: inclusion and exclusion criteria
This is a multicenter, retrospective, cohort study including patients from RENAMI registry with final diagnosis of ACS (defined according to ESC guidelines as Unstable Angina [UA], Non ST Segment Elevation Myocardial Infarction [NSTEMI] and STEMI [ST Segment Elevation Myocardial Infarction]) at Cardiology Department of following Institutions: “Città della Salute e della Scienza”, Turin; “San Luigi Gonzaga”, Orbassano; “Maggiore della Carità” Hospital, Novara; Rivoli Hospital; “San Giovanni Bosco” Hospital, Turin; “Sant’Anna” Hospital, Como; UniversitätsSpital, Zürich (Switzerland); Hospital Álvaro Cunqueiro, Vigo (Spain); Royal Brompton Hospital, London (UK); Hospital Universitari de Bellvitge, Barcelona (Spain).
Inclusion criteria were: 1) age ≥ 18 years old; 2) with diagnosis of NSTE-ACS (UA or NSTEMI) or STEMI; 3) treated with PCI and dual antiplatelet therapy using prasugrel or ticagrelor plus aspirin; 4) signed informed consent. 
Enrollment period was from 1st June 2013 to 1st June 2015. There were no exclusion criteria. Ethical approval has been released.
Clinical features
Baseline clinical features (age, gender, burden of cardiovascular risk factors, malignancy) and interventional features (Grace score, vascular access, antithrombotic therapy, kind of stent) of each patient were collected.
Dual antiplatelet therapy and major bleeding
Prasugrel and ticagrelor were provided with a loading dose of 60 mg and 180mg and a maintenance dose of 10 mg/ daily and 90 mg/ twice a day, respectively. Contraindications for prasugrel were patients with high risk of bleeding, with previous stroke/transient ischemic attack, aged >75 and with hypersensitivity to the drug or excipients. Contraindications for ticagrelor were patients with high risk of bleeding, with prior hemorrhagic stroke or intracranial bleeding, with severe hepatic dysfunction, and with hypersensitivity.
End point
Out of hospital major bleeding was defined as types 3, 4 and 5 according to BARC definition (16). MACE (Major Adverse Cardiac Events) rates, a composite of all-cause death, nonfatal myocardial infarction, unexpected revascularization (TLR/TVR) and stent thrombosis (ST), were the primary end point while secondary ones were each component of MACE, cardiovascular death, recurrence of ACS (reACS) and stroke. In hospital major bleedings (from 3 to 5 according to BARC) were a co-secondary end points.
Statistical analysis





From June 2013 to June 2015 a total of 4424 patients were enrolled. Eighty-tree  (1.8%) patients developed out of hospital  major bleedings during a follow-up of 14.1 ± 6.2 months. 31 patients (37%) developed type 3a, 39 (46%) type 3 b and 13  (15%) type 3 c bleedings.  These patients were compared with remaining 4341 (98.2%) patients without major bleeding.
At baseline (see table 1), patients with BARC 3-5 bleedings were older (65,5 ± 11,3 years vs 60.9 ± 11.5 years; p<0.001), more often aged more than 75 years old (25.3% vs 12.9%; p=0.001) and female (32.5% vs 20.6%; p=0.008), with a higher burden of cardiovascular risk factors such as hypertension (69.9% vs 53.7%, p=0.003) and dyslipidemia (65.1% vs 53.6% p=0.037), and characterized by a more marked history of previous bleeding events (7.2% vs 2.3%; p=0.004). Patients with BARC 3-5 bleedings  presented also lower levels of haemoglobin (13.5 ± 1.5 g/dL vs 14.2 ± 1.3 g/dL; p<0.001) and of haematocrit (13.5 ± 1.5 g/dL vs 14.2 ± 1.3 g/dL; p<0.001). 
In both groups STEMI (see table 2) was the most frequent clinical presentation (56.6% e 58.1%). Both in-hospital and six-months Grace scores were higher in BARC 3-5 bleeding patients (IH Grace score 221.1 ± 107.6 vs 85.5 ± 83.7 and 6 months Grace score 193.7 ± 82.8 vs 79.5 ± 62.2; p<0.001). In both groups, radial access was the most frequently used, although fewer radial access (62.7% vs 76.6%; p=0.003) and, as a consequence, more femoral access was observed in BARC 3-5 bleeding patients. Moreover, DES was less used in these patients (54.2% vs 65.9%; p=0.026). In both BARC 3-5 bleeding and without major bleeding groups prasugrel was the most frequently oral antiplatelet provided (69.9% and 61.4%, respectively). BARC 3-5 bleeding patients took statins less frequently (95.2% vs 98.7%, p=0.021), and PPIs more frequently (80.6% vs 55.7%, p=0.006), while length of DAPT did not differ (11.15± 3.264 vs. 11.95± 3.819, p 0.06). Regarding oral anticoagulation, only 60 pts overall were on OAT, and most of them were on warfarin. Of these patients, half were treated with prasugrel  and half with ticagrelor and only 2 experience a BARC MB.
Patients with BARC 3-5 bleedings had higher rates of MACE (14.5% vs 4.4%; p=0.001), all-cause death (11% vs 2.1%; p<0.001), reACS (30% vs 12.6%; p=0.021), stroke (5.2% vs 0.4%; p<0.001), and stent thrombosis (3.6% vs 1.0%; p=0.020) during a medium follow-up of 14.1 ± 6,2 months, as reported in table 3 and figure 2.
At multivariate analysis, independent predictors of major bleeding were age more than 75 years old (OR 2.00; 95% CI 1.18-3.41; p=0.010) and female sex (OR 1.66; 95% CI 1.02-2.70; p=0.041), along with 6 months grace score (OR 1,04: 1,01-1,15, 95% CI). As survival curves clearly show (figure 3), long term risk of BARC 3-5 bleedings is higher in older patients (3.6% vs 1.6%; p=0.001) and females (3.0% vs. 1.6%; p=0.032), after 12 months from starting DAT. Independent predictors of all-cause death were older age (OR 1.84; 95% CI 1.09-3.01; p=0.022), BARC 3-5 bleeding events (OR 3.46; 95% CI 1.64-7.31; p 0.001), non-insulin dependent diabetes mellitus, (OR 1.85; 95% CI 1.22-2.81; p=0.004), STEMI (OR 1.96; 95% CI 1.25-3.06; p=0.003), serum creatinine >1.5 mg/dL (OR 3,13; 95% CI 1.88-5.20; p<0.001) and multivessel coronary artery disease (OR 1.70; 95% CI 1.13-2.56; p=0.012).










The major findings of the present study are:
 1) in ACS patients treated with prasugrel and ticagrelor, major bleedings, despite being uncommon, negatively impact on prognosis;
2)  older age and female gender represent risk factors for major bleedings.
BARC 3-5 bleeding patients presented with a more relevant burden of traditional cardiovascular risk factors, as hypertension and dyslipidemia and with higher in-hospital and six-month Grace scores. 
After 14. months, BARC 3-5 bleeding patients reported higher rates of MACEs, all-cause death, stent thrombosis, stroke and reACS as already reported in several studies regarding patients with ACS (18-20), or undergoing PTCA (21-25) treated with clopidogrel. The exact mechanisms underlying the emerging relationship are not known, but may include the cessation of evidence-based therapies, mainly antiplatelet agents, beta-blockers, and/or statin therapies, in those patients who suffered bleeding complications, the direct effects of blood transfusion used to treat bleeding, or the greater prevalence of comorbidities in these patients along with a deleterious role of anemia.
This study demonstrated that age>75 years old or female gender were the main risk factors for BARC 3-5 bleeding. According to survival curves (figure 3), long term risk for BARC 3-5 bleeding increasing trend after 10 months of dual antiplatelet therapy, suggests that a shorter duration of dual antiplatelet therapy in these patients would be safer. Similar results have been provided (i) by a recent analysis (26) from Global registry of Acute Coronary Events (GRACE) including also patients treated with clopidogrel, and (ii) by comparison studies of prasugrel (27-30) and ticagrelor (30) with clopidogrel. The present study provides the first data about risk factors of major bleeding in patients treated with prasugrel and ticagrelor in the “real life”, offering clinical indications for tailoring dual antiplatelet therapy.
A direct comparison between prasugrel and ticagrelor showed asignificative (p 0.009) trend of reduction in long term risk of BARC 3-5 bleeding with prasugrel (figure 4), that disappeared at multivariate analysis, probably because prasugrel is contraindicated in patients older than 75 years old and with a weight of over  60 kg. Also Larmore et al. found lower rates of major bleeding at 30 and 90 days associated with prasugrel (RR, 0.65; 95% CI, 0.45–0.95) (16).
BARC 3-5 bleeding was independently associated with all-cause mortality and it markedly impacted negatively on prognosis as reported in figure 5, where a survival reduction of nearly 8% at 12 months and nearly 20% at 24 months (p 0.015) is reported. This is consistent with previous findings: Eikelboom  et al. found that major bleeding increased risk of over 30-days mortality (18), Ndrepepa e al. observed an increased 1-year mortality associated with BARC 3-5 bleeding (22), and finally Feit e al. demonstrated that major bleeding is an independent predictor of 1-year mortality. 
The present paper has some limitations. First all data were acquired retrospectively, consequently with bias potentially related to acquisition of data. Regarding OAT patients, not enough patients were enrolled to drive conclusion with inferential aims. Moreover we did not acquire in the RENAMI registry data of patients discharged with clopidogrel, that are commonly those at higher risk of bleedings, potentially leading to a selection bias towards lower risk. 
CONCLUSION
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